Clinical Trials Logo

Clinical Trial Summary

The trial assess the progression-free survival (PFS) two years after autologous stem cell transplantation (ASCT) in high-risk DLBCL patients receiving PD-L1 inhibition with durvalumab.


Clinical Trial Description

Background and Rationale:

Autologous stem cell transplantation (ASCT) is standard of care in the treatment concept of adult patients with multiple myeloma (MM), malignant lymphomas (including diffuse large B-cell lymphomas (DLBCL), mantle cell lymphomas, follicular lymphomas or T-cell lymphomas), acute myeloid leukemia (AML) and relapsing germ cell tumors. The number of patients treated with ASCT is steadily increasing, e.g. by +17% alone in Switzerland in the year 2015, to a total of 464 ASCT per year in Switzerland. The Inselspital (University Hospital) in Berne is the leading hospital in Switzerland for ASCT, with 145 ASCT in the year 2015. Among these 145 transplants, 31 patients had DLBCL.

The goal of treatment in DLBCL is definite cure. In DLBCL, the addition of anti-CD20 treatment to standard CHOP (Cyclophosphamid, Doxorubicin, Vincristine, Prednisone) chemotherapy has improved the cure rate after R-CHOP (Rituximab-CHOP) first-line treatment. Nevertheless, the disease is relapsing in roughly 20% of these patients. At relapse, patients are treated with salvage chemotherapy such as the R-DHAP (Rituximab, Dexamethasone, Cisplatin,Cytarabine), or R-ICE (Rituximab,Ifosfamide, Carboplatin, Etoposide) regimens, followed by BEAM (BCNU, Etoposide, Cytarabine, Melphalan) or BeEAM (Bendamustin, Etoposide, Cyclophosphamide, Melphalan) high-dose chemotherapy supported with ASCT. The overall survival rate at the Inselspital Bern and elsewhere at two years for DLBCL patients after ASCT is 60%, and, therefore, improving outcome of such patients remains an unmet clinical need. This is particularly true in high-risk DLBCL patients, such as in DLBCL patients relapsing within 12 months after first-line treatment as well as in DLBCL patients not achieving a (first or second) complete remission (CR) after induction treatment before ASCT. PFS at two years for such high-risk lymphoma patients is 50% at the investigators' institution.

Immunotherapy (such as with PD-L1 inhibition) after ASCT is a promising approach to potentially improve results after ASCT. A first study applying PD-1 inhibition with three applications (every 42 days) of Pidilizumab started between days 30 and 90 after ASCT showed a promising progression-free survival rate of 72% in relapsing DLBCL patients at 16 months after the first Pidilizumab application. These data suggest that immunotherapy after ASCT has the potential to a meaningful improvement of survival rates in DLBCL patients after ASCT.

Objective:

The primary objective of this Trial is to show a progression-free survival of 70% two years after autologous stem cell transplantation (ASCT) in high-risk DLBCL patients receiving PD-L1 inhibition with durvalumab.

Study Duration:

The 46 patients needed in this study will be included within 24 months. Additional 24 months will be needed until the last study patient reaches PFS at 2 years. Accordingly, the total study duration is expected to be 48 months. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03241017
Study type Interventional
Source University Hospital Inselspital, Berne
Contact
Status Withdrawn
Phase Phase 2
Start date October 2017
Completion date December 2021

See also
  Status Clinical Trial Phase
Recruiting NCT03977623 - Genomic Evaluation in Patients With Diffuse Large B Cell Lymphoma After First Relapse/Progression
Recruiting NCT02428751 - R-CHOP Versus R-CDOP as First-line Treatment for Elderly Patients With Diffuse Large-B-cell Lymphoma Phase 3
Completed NCT02555267 - Geriatric Assessments in Elderly Diffuse Large B-cell Lymphoma
Active, not recruiting NCT02364050 - Prospective Data Collection of Elderly Patients With DLBCL Receiving at the Time of Diagnosis VGM
Terminated NCT00529503 - A Randomized Phase IIb Placebo-Controlled Study of R-ICE Chemotherapy With and Without SGN-40 for Patients With DLBCL Phase 2
Terminated NCT02413489 - An Efficacy and Safety Proof of Concept Study of Daratumumab in Relapsed/Refractory Mantle Cell Lymphoma, Diffuse Large B-Cell Lymphoma, and Follicular Lymphoma Phase 2
Completed NCT02086604 - Brentuximab Vedotin and Lenalidomide for Relapsed or Refractory Diffuse Large B-cell Lymphoma Phase 1
Completed NCT01421524 - Study of CC-122 to Evaluate the Safety, Tolerability, and Effectiveness for Patients With Advanced Solid Tumors, Non-Hodgkin's Lymphoma, or Multiple Myeloma Phase 1
Recruiting NCT03600363 - A Clinical Trial of Metformin in the Maintenance of Non-Hodgkin's Lymphoma Patients Phase 2
Recruiting NCT03646422 - AEDV Registry of Primary Cutaneous Lymphoma
Recruiting NCT04446962 - LOC-R01 Study of Lenalidomide and Ibrutinib in Association With Rituximab-Methotrexate Procarbazine Vincristin (R-MPV) Phase 1/Phase 2
Recruiting NCT02928861 - 18F-FDG PET/CT-based Prognostic Model for Predicting Outcome in Patients With Diffuse Large B-cell Lymphoma N/A
Recruiting NCT02931201 - Evaluating 18F-FDG PET/CT With Liver SUVmax-based Criteria for Prognosis of Patients With Diffuse Large B-cell Lymphoma N/A
Terminated NCT02592876 - Treatment Study of Denintuzumab Mafodotin (SGN-CD19A) Plus RICE Versus RICE Alone for Diffuse Large B-Cell Lymphoma Phase 2
Completed NCT00849147 - Bone Marrow Transplant From Partially Matched Donors and Nonmyeloablative Conditioning for Blood Cancers (BMT CTN 0603) Phase 2
Completed NCT00822432 - Coproporphyrine Isomers and Methotrexate Elimination N/A
Completed NCT03682796 - Study of TRPH-222 in Patients With Relapsed and/or Refractory B-Cell Lymphoma Phase 1
Recruiting NCT04982471 - Connect® Lymphoma Disease Registry: A US-Based Prospective Observational Cohort Study
Completed NCT03744676 - A Safety Trial of Lisocabtagene Maraleucel (JCAR017) for Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL) in the Outpatient Setting (TRANSCEND-OUTREACH-007) Phase 2
Completed NCT03310619 - A Safety and Efficacy Trial of JCAR017 Combinations in Subjects With Relapsed/Refractory B-cell Malignancies Phase 1/Phase 2